Analysts See $1.26 EPS for Quaker Chemical Corporation (KWR)

Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.27, from 1.34 in 2017Q2. It dived, as 12 investors sold Quaker Chemical Corporation shares while 49 reduced holdings. 23 funds opened positions while 42 raised stakes. 10.69 million shares or 2.22% less from 10.93 million shares in …

February 22, 2018 – By reb123z

 Analysts See $1.26 EPS for Quaker Chemical Corporation (KWR)
Investors sentiment decreased to 1.07 in 2017 Q3. Its down 0.27, from 1.34 in 2017Q2. It dived, as 12 investors sold Quaker Chemical Corporation shares while 49 reduced holdings. 23 funds opened positions while 42 raised stakes. 10.69 million shares or 2.22% less from 10.93 million shares in 2017Q2 were reported.

Brown Brothers Harriman Communication holds 86 shares. Sg Americas Secs Ltd Com owns 2,159 shares for 0% of their portfolio. Glenmede Na accumulated 40 shares. Legal General Grp Public Ltd Company invested 0% of its portfolio in Quaker Chemical Corporation (NYSE:KWR). Louisiana State Employees Retirement System owns 5,400 shares. Mark Sheptoff Planning Llc stated it has 2,424 shares. Swiss Bancorporation has 22,400 shares for 0% of their portfolio. Jefferies Group Inc Ltd invested in 3,608 shares. Victory Management Inc holds 113,515 shares. Jacobs Levy Equity Mngmt Inc holds 0.01% of its portfolio in Quaker Chemical Corporation (NYSE:KWR) for 3,169 shares. First Trust Advsr Lp reported 13,411 shares. Deutsche Financial Bank Ag accumulated 0% or 11,941 shares. Oppenheimer Asset Mgmt holds 4,018 shares. Aqr Capital Management Ltd has 3,996 shares for 0% of their portfolio. Regions Fincl Corp reported 1,405 shares.

Since September 1, 2017, it had 0 buys, and 4 insider sales for $590,000 activity.

Analysts expect Quaker Chemical Corporation (NYSE:KWR) to report $1.26 EPS on February, 28 after the close.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $1.26 EPS. KWR’s profit would be $16.76 million giving it 29.35 P/E if the $1.26 EPS is correct. After having $1.33 EPS previously, Quaker Chemical Corporation’s analysts see -5.26 % EPS growth. The stock increased 0.59% or $0.87 during the last trading session, reaching $147.91. About 50,670 shares traded. Quaker Chemical Corporation (NYSE:KWR) has risen 66.07% since February 22, 2017 and is uptrending. It has outperformed by 49.37% the S&P500.

Quaker Chemical Corporation (NYSE:KWR) Ratings Coverage

Among 5 analysts covering Quaker Chemical Corp (NYSE:KWR), 0 have Buy rating, 0 Sell and 5 Hold. Therefore 0 are positive. Quaker Chemical Corp had 14 analyst reports since August 6, 2015 according to SRatingsIntel. As per Wednesday, January 13, the company rating was upgraded by Seaport Global. Seaport Global downgraded the stock to “Neutral” rating in Monday, May 2 report. The stock of Quaker Chemical Corporation (NYSE:KWR) has “Hold” rating given on Monday, October 16 by Jefferies. On Thursday, August 31 the stock rating was maintained by Jefferies with “Hold”. Jefferies downgraded the stock to “Hold” rating in Tuesday, February 16 report. Jefferies maintained the shares of KWR in report on Friday, April 7 with “Hold” rating. The rating was maintained by Jefferies with “Hold” on Thursday, June 15. Jefferies maintained it with “Hold” rating and $15300 target in Wednesday, July 19 report. The rating was downgraded by Zacks on Thursday, August 6 to “Buy”. The stock of Quaker Chemical Corporation (NYSE:KWR) has “Hold” rating given on Thursday, October 27 by Wunderlich.

Quaker Chemical Corporation develops, produces, and markets various formulated chemical specialty products for various heavy industrial and manufacturing applications worldwide. The company has market cap of $1.97 billion. The Company’s products include rolling lubricants used by manufacturers of steel in the hot and cold rolling of steel, and aluminum in the hot rolling of aluminum; machining and grinding compounds for use in cutting, shaping, and grinding metal parts; hydraulic fluids for steel, metalworking, and other clients to operate hydraulic equipment; corrosion preventives to protect metals during manufacture, storage, and shipment; and specialty greases used in automotive production processes, steel manufacturing, and various other applications. It has a 41.61 P/E ratio. The firm also provides metal finishing compounds to prepare metal surfaces for special treatments, such as galvanizing and tin plating, as well as to prepare metal for further processing; forming compounds used to facilitate the drawing and extrusion of metal products; chemical milling maskants for the aerospace industry; and temporary and permanent coatings for metal and concrete products.

More notable recent Quaker Chemical Corporation (NYSE:KWR) news were published by: Philly.com which released: “Quaker Chemical to acquire rival Houghton” on April 05, 2017, also Prnewswire.com with their article: “Showcasing Mining Compliance Solutions and Technical Expertise” published on February 20, 2018, Prnewswire.com published: “Quaker Acquires Remaining Interest In India Joint Venture” on December 21, 2017. More interesting news about Quaker Chemical Corporation (NYSE:KWR) were released by: Reuters.com and their article: “BRIEF-Quaker Chemical and Houghton International to combine” published on April 05, 2017 as well as Prnewswire.com‘s news article titled: “Quaker Chemical Hosts Health, Safety and Environmental Solutions Seminar in Chile” with publication date: November 17, 2017.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

EPS for Eclipse Resources Corporation (ECR) Expected At $-0.01

Aqr Capital Management Lc stated it has 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR). State Board Of Administration Of Florida Retirement System invested 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR). Brown Advisory Securities Lc stated it has 25,000 shares.

February 22, 2018 – By Nellie Frank

 EPS for Eclipse Resources Corporation (ECR) Expected At $ 0.01
Investors sentiment decreased to 1.2 in 2017 Q3. Its down 0.02, from 1.22 in 2017Q2. It dropped, as 12 investors sold Eclipse Resources Corporation shares while 23 reduced holdings. 13 funds opened positions while 29 raised stakes. 60.52 million shares or 4.79% less from 63.57 million shares in 2017Q2 were reported.

392,878 are held by D E Shaw And. Aperio Grp Incorporated Limited Liability stated it has 12,128 shares or 0% of all its holdings. 80,583 are owned by Manufacturers Life Ins The. Goldman Sachs Grp Inc holds 0% or 163,751 shares in its portfolio. Great West Life Assurance Can has invested 0% in Eclipse Resources Corporation (NYSE:ECR). Rhumbline Advisers invested in 98,885 shares. Kohlberg Kravis Roberts Lp, New York-based fund reported 11.05 million shares. Virginia Retirement Et Al reported 0% in Eclipse Resources Corporation (NYSE:ECR). Voya Investment Mgmt Ltd holds 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR) for 38,699 shares. California Employees Retirement System stated it has 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR). Vanguard Gp holds 5.31M shares. Aqr Capital Management Lc stated it has 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR). State Board Of Administration Of Florida Retirement System invested 0% of its portfolio in Eclipse Resources Corporation (NYSE:ECR). Brown Advisory Securities Lc stated it has 25,000 shares. Schwab Charles Inv Mngmt Incorporated accumulated 366,855 shares.

Analysts expect Eclipse Resources Corporation (NYSE:ECR) to report $-0.01 EPS on February, 28 after the close.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.03 EPS previously, Eclipse Resources Corporation’s analysts see -66.67 % EPS growth. The stock increased 0.61% or $0.01 during the last trading session, reaching $1.66. About 628,645 shares traded. Eclipse Resources Corporation (NYSE:ECR) has declined 1.59% since February 22, 2017 and is downtrending. It has underperformed by 18.29% the S&P500.

Eclipse Resources Corporation (NYSE:ECR) Ratings Coverage

Among 20 analysts covering Eclipse Resources (NYSE:ECR), 11 have Buy rating, 1 Sell and 8 Hold. Therefore 55% are positive. Eclipse Resources had 56 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Tuesday, September 5 with “Hold”. The company was maintained on Wednesday, January 18 by Fundamental Research. The rating was maintained by Stifel Nicolaus on Wednesday, September 13 with “Buy”. The stock of Eclipse Resources Corporation (NYSE:ECR) earned “Hold” rating by BMO Capital Markets on Wednesday, August 2. Barclays Capital maintained the shares of ECR in report on Thursday, May 25 with “Hold” rating. The stock has “Equal-Weight” rating by Barclays Capital on Wednesday, October 11. The stock has “Neutral” rating by Seaport Global on Friday, December 9. The firm has “Buy” rating by Johnson Rice given on Monday, December 11. On Monday, November 20 the stock rating was maintained by KeyBanc Capital Markets with “Buy”. The stock of Eclipse Resources Corporation (NYSE:ECR) earned “Buy” rating by RBC Capital Markets on Tuesday, October 3.

Eclipse Resources Corporation, an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. The company has market cap of $498.94 million. The firm owns interests in the Utica Shale and Marcellus Shale areas. It currently has negative earnings. As of December 31, 2016, it had an acreage position approximating 199,000 net acres in Eastern Ohio.

More recent Eclipse Resources Corporation (NYSE:ECR) news were published by: Businesswire.com which released: “Eclipse Resources Corporation Schedules Fourth Quarter and Full Year 2017 …” on February 13, 2018. Also Businesswire.com published the news titled: “Eclipse Resources Corporation Announces Agreements to Acquire New Utica …” on December 11, 2017. Businesswire.com‘s news article titled: “Eclipse Resources Reports Proved Reserves, Operational and Financial Update” with publication date: January 31, 2018 was also an interesting one.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Eclipse Resources Corporation (ECR) Analysts See $-0.01 EPS

Kohlberg Kravis Roberts And L P holds 0.32% or 11.05 million shares. Analysts expect Eclipse Resources Corporation (NYSE:ECR) to report $-0.01 EPS on February, 28 after the close.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.03 EPS previously, …

February 22, 2018 – By Dolores Ford

 Eclipse Resources Corporation (ECR) Analysts See $ 0.01 EPS
Investors sentiment decreased to 1.2 in 2017 Q3. Its down 0.02, from 1.22 in 2017Q2. It turned negative, as 12 investors sold Eclipse Resources Corporation shares while 23 reduced holdings. 13 funds opened positions while 29 raised stakes. 60.52 million shares or 4.79% less from 63.57 million shares in 2017Q2 were reported.

Tiaa Cref Investment Management accumulated 661,772 shares. Hbk Limited Partnership owns 11,600 shares for 0% of their portfolio. Aqr Cap Management Limited reported 53,245 shares. Nationwide Fund Advisors reported 527,480 shares. Two Sigma Secs Limited Liability has invested 0.01% in Eclipse Resources Corporation (NYSE:ECR). Sg Americas Securities Limited Liability Corp owns 21,369 shares. Alliancebernstein Limited Partnership invested 0% in Eclipse Resources Corporation (NYSE:ECR). Swiss Bank accumulated 146,200 shares or 0% of the stock. Ameritas Inv Prtnrs holds 0% or 4,808 shares in its portfolio. Blackrock Inc has 9.00 million shares for 0% of their portfolio. Invesco Limited accumulated 0% or 158,973 shares. Blackstone Group Inc L P holds 3.41 million shares. Tower Capital (Trc) holds 0% or 3,900 shares. Deutsche Fincl Bank Ag holds 93,826 shares. Kohlberg Kravis Roberts And L P holds 0.32% or 11.05 million shares.

Analysts expect Eclipse Resources Corporation (NYSE:ECR) to report $-0.01 EPS on February, 28 after the close.They anticipate $0.01 EPS change or 50.00 % from last quarter’s $-0.02 EPS. After having $-0.03 EPS previously, Eclipse Resources Corporation’s analysts see -66.67 % EPS growth. The stock increased 0.61% or $0.01 during the last trading session, reaching $1.66. About 628,645 shares traded. Eclipse Resources Corporation (NYSE:ECR) has declined 1.59% since February 22, 2017 and is downtrending. It has underperformed by 18.29% the S&P500.

Eclipse Resources Corporation (NYSE:ECR) Ratings Coverage

Among 20 analysts covering Eclipse Resources (NYSE:ECR), 11 have Buy rating, 1 Sell and 8 Hold. Therefore 55% are positive. Eclipse Resources had 56 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Eclipse Resources Corporation (NYSE:ECR) earned “Buy” rating by RBC Capital Markets on Monday, August 7. As per Wednesday, January 13, the company rating was downgraded by Seaport Global. Topeka Capital Markets maintained it with “Buy” rating and $5 target in Monday, October 12 report. KeyBanc Capital Markets maintained Eclipse Resources Corporation (NYSE:ECR) rating on Monday, November 20. KeyBanc Capital Markets has “Buy” rating and $3.25 target. Seaport Global downgraded Eclipse Resources Corporation (NYSE:ECR) on Wednesday, June 21 to “Neutral” rating. The firm earned “Buy” rating on Monday, February 6 by Seaport Global Securities. The firm has “Hold” rating given on Tuesday, August 4 by Deutsche Bank. The firm earned “Buy” rating on Friday, June 2 by RBC Capital Markets. As per Tuesday, October 10, the company rating was maintained by BMO Capital Markets. As per Wednesday, June 21, the company rating was maintained by BMO Capital Markets.

Eclipse Resources Corporation, an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. The company has market cap of $498.94 million. The firm owns interests in the Utica Shale and Marcellus Shale areas. It currently has negative earnings. As of December 31, 2016, it had an acreage position approximating 199,000 net acres in Eastern Ohio.

More recent Eclipse Resources Corporation (NYSE:ECR) news were published by: Businesswire.com which released: “Eclipse Resources Reports Proved Reserves, Operational and Financial Update” on January 31, 2018. Also Businesswire.com published the news titled: “Eclipse Resources Corporation Announces Agreements to Acquire New Utica …” on December 11, 2017. Businesswire.com‘s news article titled: “Eclipse Resources Corporation Schedules Fourth Quarter and Full Year 2017 …” with publication date: February 13, 2018 was also an interesting one.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Related Posts:

  • No Related Posts

Terrance F. Spidell Sells 8409 Shares of Juniper Networks, Inc. (JNPR) Stock

Juniper Networks logo Juniper Networks, Inc. (NYSE:JNPR) VP Terrance F. Spidell sold 8,409 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $26.47, for a total value of $222,586.23. The sale was disclosed in a legal filing with the …

Juniper Networks logoJuniper Networks, Inc. (NYSE:JNPR) VP Terrance F. Spidell sold 8,409 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $26.47, for a total value of $222,586.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Juniper Networks, Inc. (NYSE JNPR) traded down $0.34 during trading hours on Wednesday, hitting $25.89. The company had a trading volume of 4,678,496 shares, compared to its average volume of 4,569,286. The company has a market cap of $9,879.36, a P/E ratio of 31.96, a PEG ratio of 3.06 and a beta of 0.89. The company has a current ratio of 2.41, a quick ratio of 2.70 and a debt-to-equity ratio of 0.46. Juniper Networks, Inc. has a 52 week low of $23.87 and a 52 week high of $30.96.

Juniper Networks (NYSE:JNPR) last announced its quarterly earnings data on Tuesday, January 30th. The network equipment provider reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.01. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.23 billion. Juniper Networks had a return on equity of 13.34% and a net margin of 6.26%. The firm’s revenue was down 10.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 EPS. research analysts predict that Juniper Networks, Inc. will post 1.34 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 22nd. Investors of record on Thursday, March 1st will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Wednesday, February 28th. This is an increase from Juniper Networks’s previous quarterly dividend of $0.10. This represents a $0.72 dividend on an annualized basis and a dividend yield of 2.78%. Juniper Networks’s payout ratio is 49.38%.

Juniper Networks declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 30th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the network equipment provider to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

A number of equities analysts have weighed in on JNPR shares. Deutsche Bank reissued a “sell” rating and issued a $20.00 target price on shares of Juniper Networks in a research report on Friday, January 5th. Cowen reissued a “hold” rating and issued a $28.00 target price on shares of Juniper Networks in a research report on Friday, October 27th. Wells Fargo & Co started coverage on Juniper Networks in a research report on Tuesday, November 14th. They issued a “market perform” rating and a $25.00 target price for the company. ValuEngine raised Juniper Networks from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. Finally, Raymond James Financial set a $31.00 target price on Juniper Networks and gave the stock a “buy” rating in a research report on Thursday, December 7th. Five equities research analysts have rated the stock with a sell rating, eighteen have given a hold rating and eight have assigned a buy rating to the company. Juniper Networks currently has a consensus rating of “Hold” and an average target price of $28.61.

Several large investors have recently made changes to their positions in the stock. Xact Kapitalforvaltning AB grew its stake in shares of Juniper Networks by 7.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 61,518 shares of the network equipment provider’s stock valued at $1,753,000 after acquiring an additional 4,029 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of Juniper Networks by 7.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 73,678 shares of the network equipment provider’s stock valued at $2,099,000 after acquiring an additional 4,969 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its stake in shares of Juniper Networks by 7.4% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 158,105 shares of the network equipment provider’s stock valued at $4,506,000 after acquiring an additional 10,854 shares during the period. Fairpointe Capital LLC grew its stake in shares of Juniper Networks by 3.6% during the 4th quarter. Fairpointe Capital LLC now owns 6,264,209 shares of the network equipment provider’s stock valued at $178,530,000 after acquiring an additional 216,254 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Juniper Networks during the 4th quarter valued at approximately $3,306,000. Institutional investors own 86.51% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Terrance F. Spidell Sells 8,409 Shares of Juniper Networks, Inc. (JNPR) Stock” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/21/terrance-f-spidell-sells-8409-shares-of-juniper-networks-inc-jnpr-stock.html.

Juniper Networks Company Profile

Juniper Networks, Inc designs, develops and sells products and services for high-performance networks to enable customers to build networks for their businesses. The Company sells its products in over 100 countries in three geographic regions: Americas; Europe, the Middle East and Africa, and Asia Pacific.

Insider Buying and Selling by Quarter for Juniper Networks (NYSE:JNPR)

Receive News & Ratings for Juniper Networks Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Juniper Networks and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Acadian Asset Management LLC Has $1.60 Million Stake in Summit Therapeutics PLC (SMMT)

Summit Therapeutics logo Acadian Asset Management LLC increased its position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 192.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 144,083 shares of the company’s stock after …

Summit Therapeutics logoAcadian Asset Management LLC increased its position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 192.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 144,083 shares of the company’s stock after purchasing an additional 94,876 shares during the quarter. Acadian Asset Management LLC owned approximately 1.04% of Summit Therapeutics worth $1,595,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Susquehanna International Group LLP purchased a new position in shares of Summit Therapeutics during the 3rd quarter worth $1,828,000. Granite Point Capital Management L.P. lifted its stake in Summit Therapeutics by 106.7% during the 3rd quarter. Granite Point Capital Management L.P. now owns 242,113 shares of the company’s stock worth $3,031,000 after acquiring an additional 125,000 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in Summit Therapeutics during the 3rd quarter worth about $1,004,000. Sphera Funds Management LTD. lifted its stake in Summit Therapeutics by 49.3% during the 3rd quarter. Sphera Funds Management LTD. now owns 212,018 shares of the company’s stock worth $2,654,000 after acquiring an additional 70,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in Summit Therapeutics during the 3rd quarter worth about $628,000. Hedge funds and other institutional investors own 30.25% of the company’s stock.

SMMT has been the topic of a number of analyst reports. Oppenheimer increased their price target on Summit Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, January 26th. HC Wainwright set a $16.00 target price on Summit Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research lowered Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, December 28th. ValuEngine raised Summit Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BTIG Research started coverage on Summit Therapeutics in a research note on Tuesday, February 13th. They set a “buy” rating and a $33.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. Summit Therapeutics has a consensus rating of “Buy” and a consensus target price of $24.17.

Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded down $0.05 during mid-day trading on Wednesday, hitting $11.37. The company’s stock had a trading volume of 20,298 shares, compared to its average volume of 117,049. The stock has a market cap of $161.70, a P/E ratio of -113.70 and a beta of 0.73. Summit Therapeutics PLC has a one year low of $8.80 and a one year high of $16.86.

Summit Therapeutics (NASDAQ:SMMT) last posted its quarterly earnings results on Wednesday, December 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.53. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.32 million. Summit Therapeutics had a negative return on equity of 10.90% and a negative net margin of 0.95%. research analysts expect that Summit Therapeutics PLC will post -0.46 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://ledgergazette.com/2018/02/22/summit-therapeutics-plc-smmt-position-boosted-by-acadian-asset-management-llc.html.

Summit Therapeutics Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Institutional Ownership by Quarter for Summit Therapeutics (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Summit Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts